Effects of Heparin on the Inhibitory Activities of Human Urinary Trypsin Inhibitor (Ulinastatin) on Trypsin, Chymotrypsin and Leukocyte Elastase

Saito, T; Hagihara, Asako; Igarashi, Naoko; Matsuda, Naomi; Yamashita, Akira; Ito, Keizo; Mio, Mitsunobu; Tasaka, Kenjí

doi:10.1254/jjp.62.137

Cited by 34 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies have demonstrated that several types of receptors, such as NK1 receptor, exist for SP (18). More recently, some antiallergic drugs have been suggested to possess a binding affinity for SP receptors (19). This raises the possibility that antiallergics occupy SP receptors in an antagonistic fashion, resulting in the elevation of circulating SP.…”

Section: Discussionmentioning

confidence: 99%

The Various Effects of Four H1-Antagonists on Serum Substance P Levels in Patients with Atopic Dermatitis

Izu

Tokura

2005

The Journal of Dermatology

View full text Add to dashboard Cite

Antiallergic drugs have various actions against allergy-associated cells and molecules as well as antihistamic properties. We studied the effects of antiallergics on the serum levels of substance P. Patients with atopic dermatitis were treated with one of four oral H1-antagonists for 14 days, and the serum level of substance P was measured before and after treatment in parallel with several atopic severity markers. Olopatadine significantly decreased the substance P level. This is in accordance with its known downmodulatory effect on tachykinin release. In contrast, cetiridine and fexofenadine unexpectedly increased the substance P level. In patients administered cetiridine, the blood severity markers for atopic dermatitis, including lactate dehydrogenase, eosinophil number, and the soluble forms of IL-2R, E-selectin, VCAM-1 and ICAM-1 were reduced after the treatment. Therefore, the elevation of SP was unrelated to the deterioration of atopic dermatitis but rather associated with improvement. Our study suggests that antiallergics can be divided into substance P-increasing and -decreasing types and raises the possibility that the increment of substance P by the former type is caused by the competitive occupation of substance P receptors.

show abstract

Section: Discussionmentioning

confidence: 99%

The Various Effects of Four H1-Antagonists on Serum Substance P Levels in Patients with Atopic Dermatitis

Izu

Tokura

2005

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…produced significant inhibition of passive peritoneal anaphylaxis in guinea-pigs, while ketotifen fumarate was ineffective even at 0.3 mg/kg, p.o. These results indicate that the clinical antiallergic effects of emedastine difumarate involved the inhibition of histamine release [57].…”

Section: Pharmacodynamicsmentioning

confidence: 72%

Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases

Murota

Katayama

2009

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Emedastine is an H 1 antagonist and therefore affects the signs and symptoms initiated by histamine binding to the H 1 receptor. In preclinical studies, emedastine was extremely efficacious in inhibiting the histamine release (7) and eosinophil chemotaxis (8).…”

Section: Discussionmentioning

confidence: 99%

An Efficacy and Tolerance Comparison of Emedastine Difumarate 0.05% and Levocabastine Hydrochloride 0.05%: Reducing Chemosis and Eyelid Swelling in Subjects with Seasonal Allergic Conjunctivitis

Ag¹,

Leonardi²,

Discepola³

et al. 2000

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

ABSTRACT.Purpose: To compare emedastine ophthalmic solution 0.05% BID to levocabastine ophthalmic suspension 0.05% BID in reducing chemosis, eyelid swelling and other signs and symptoms in subjects with seasonal allergic conjunctivitis. Methods: In a randomized, double-masked, parallel controlled study, emedastine ophthalmic solution 0.05% BID was compared to levocabastine ophthalmic suspension 0.05% BID for control of chemosis, eyelid swelling and other parameters in the environmental allergy study model. Results: At Days 7, 14, 30 and 42, emedastine was significantly better than levocabastine at controlling chemosis and eyelid swelling (p∞0.05). A statistical trend was seen at Day 3 (0.05∞p∞0.10). Results were clinically relevant at Days 30 and 42. Emedastine was also significantly better at reducing redness and itching at Days 7, 14, 30 and 42 (p∞0.05). Conclusion: Emedastine is more efficacious than levocabastine in reducing chemosis, eyelid swelling and other efficacy variables associated with seasonal allergic conjunctivitis.

show abstract

Effects of Heparin on the Inhibitory Activities of Human Urinary Trypsin Inhibitor (Ulinastatin) on Trypsin, Chymotrypsin and Leukocyte Elastase

Cited by 34 publications

References 22 publications

The Various Effects of Four H1-Antagonists on Serum Substance P Levels in Patients with Atopic Dermatitis

The Various Effects of Four H1-Antagonists on Serum Substance P Levels in Patients with Atopic Dermatitis

Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases

An Efficacy and Tolerance Comparison of Emedastine Difumarate 0.05% and Levocabastine Hydrochloride 0.05%: Reducing Chemosis and Eyelid Swelling in Subjects with Seasonal Allergic Conjunctivitis

Contact Info

Product

Resources

About